Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) was upgraded by equities research analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.
Chugai Pharmaceutical Trading Down 2.1%
Chugai Pharmaceutical stock opened at $27.52 on Tuesday. The firm has a 50-day moving average of $26.72 and a 200-day moving average of $24.39. The firm has a market cap of $90.57 billion, a P/E ratio of 34.40 and a beta of 0.63. Chugai Pharmaceutical has a 1-year low of $19.50 and a 1-year high of $31.26.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Read More
- Five stocks we like better than Chugai Pharmaceutical
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
